Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis

Author： Gennari Luigi   Merlotti Daniela   Stolakis Konstantinos   Nuti Ranuccio  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.6, Iss.2, 2011-02, pp. : 205-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas

By Maruo Takeshi   Ohara Noriyuki   Yoshida Shigeki   Nakabayashi Koji   Sasaki Hiroko   Xu Qin   Matsuo Hiroya   Sitruk-Ware Regine   Yamada Hideto  

Expert Opinion on Drug Discovery, Vol. 6, Iss. 9, 2011-09 ,pp. : 897-911

Informa Healthcare

Access to resources Recommend Favorite

Clodronic Acid in the Treatment of Postmenopausal Osteoporosis

By Tanakol Refik  

Clinical Drug Investigation, Vol. 27, Iss. 6, 2007-01 ,pp. : 419-433

Adis International

Access to resources Recommend Favorite

Denosumab: A Review of its Use in the Treatment of Postmenopausal Osteoporosis

By Moen Marit D.   Keam Susan J.  

Drugs & Aging, Vol. 28, Iss. 1, 2011-01 ,pp. : 63-82

Adis International

Access to resources Recommend Favorite

Risedronate for prevention and treatment of osteoporosis in postmenopausal women

By Recker Robert R   Barger-Lux Janet  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 3, 2005-03 ,pp. : 465-477

Informa Healthcare

Access to resources Recommend Favorite

Parathyroid hormone and related peptides for the treatment of postmenopausal osteoporosis

By Dietrich J.W.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 6, 1997-06 ,pp. : 655-664

Informa Healthcare

Access to resources Recommend Favorite